Abstract
The health crisis due to coronavirus disease 2019 (COVID-19) has shocked the world, with more than 1 million infections and casualties. COVID-19 can present from mild illness to multi-organ involvement, but especially acute respiratory distress syndrome. Cardiac injury and arrhythmias, including atrial fibrillation (AF), are not uncommon in COVID-19. COVID-19 is highly contagious, and therapy against the virus remains premature and largely unknown, which makes the management of AF patients during the pandemic particularly challenging. We describe a possible pathophysiological link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.
Keywords:
Ablation; Antiarrhythmic drugs; Atrial fibrillation; Oral anticoagulation.
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use*
-
Angiotensin-Converting Enzyme 2
-
Anti-Arrhythmia Agents / therapeutic use*
-
Anticoagulants / therapeutic use*
-
Antiviral Agents / therapeutic use*
-
Atrial Fibrillation / drug therapy*
-
Atrial Fibrillation / physiopathology
-
Betacoronavirus*
-
COVID-19
-
COVID-19 Drug Treatment
-
Catheter Ablation / methods
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / epidemiology*
-
Coronavirus Infections / physiopathology
-
Coronavirus Infections / virology
-
Cytokines / blood
-
Drug Interactions
-
Humans
-
Pandemics
-
Peptidyl-Dipeptidase A / metabolism
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / epidemiology*
-
Pneumonia, Viral / physiopathology
-
Pneumonia, Viral / virology
-
Risk
-
SARS-CoV-2
Substances
-
Adrenergic beta-Antagonists
-
Anti-Arrhythmia Agents
-
Anticoagulants
-
Antiviral Agents
-
Cytokines
-
Peptidyl-Dipeptidase A
-
ACE2 protein, human
-
Angiotensin-Converting Enzyme 2